%0 Journal Article
%T Management of benign prostatic hyperplasia with silodosin
%A Tomonori Yamanishi
%A Tomoya Mizuno Takao Kamai
%A et al
%J Open Access Journal of Urology
%D 2009
%I 
%X Tomonori Yamanishi1, Tomoya Mizuno1, Takao Kamai1, Ken-ichiro Yoshida1, Ryuji Sakakibara2, Tomoyuki Uchiyama31Department of Urology, Dokkyo Medical University, Tochigi, Japan; 2Department of Neurology, Sakura Hospital, Toho University, Toho, Japan; 3Department of Neurology, Chiba University, Chiba, JapanAbstract: It has been reported that blockade of ¦Á1A-adrenoceptor (AR) relieves bladder outlet obstruction, while blockade of ¦Á1D-AR is believed to alleviate storage symptoms due to detrusor overactivity. Silodosin, (-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2trifluoroethoxy) phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7- carboxamide, is a new ¦Á1A-AR selective antagonist. Silodosin is highly selective for the ¦Á1A-AR subtype, showing an affinity for the ¦Á1A-AR that is 583- and 55.5-fold higher than its affinity for the ¦Á1B- and ¦Á1D-ARs, respectively. In randomized, double-blind, placebo-controlled phase III studies performed in Japan and the United States, silodosin has been shown to be effective for both storage and voiding symptoms associated with benign prostatic hyperplasia. Early effects of silodosin (after 2¨C6 hours or day 1) on lower urinary tract symptoms have also been reported. In urodynamic studies, detrusor overactivity disappeared in 40% and improved in 35% of patients after administration. In pressure flow studies, the grade of obstruction on the International Continence Society nomogram showed improvement in 56% of patients. The rate of adverse events in the silodosin, tamsulosin and placebo groups was 88.6%, 82.3%, and 71.6%, respectively. The most common adverse event was (mostly mild) abnormal ejaculation (28.1%). However, few patients (2.8%) discontinued silodosin because of abnormal ejaculation. Orthostatic hypotension showed a similar incidence in the silodosin (2.6%) and placebo (1.5%) groups. In conclusion, silodosin improves detrusor overactivity and obstruction and thus may be effective for both storage and voiding symptoms in patients with benign prostatic hyperplasia.Keywords: alpha-blocker, silodosin, benign prostatic hyperplasia, lower urinary tract symptoms
%U http://www.dovepress.com/management-of-benign-prostatic-hyperplasia-with-silodosin-a3468